New drug combo tested to keep aggressive prostate cancer in check
NCT ID NCT04947254
Summary
This study is testing if adding a drug called niraparib to standard hormone therapy after radiation treatment works better at controlling high-risk prostate cancer that is still in the prostate area or nearby lymph nodes. It will enroll about 200 men. The goal is to see if this combination helps keep the cancer from growing or returning for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIC PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.